ArticleTherapeutic advances in gastroenterology2025

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings.

Koshiro Fukuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.